Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

This study has been completed.
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Ahmad Tarhini, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00374140
First received: September 6, 2006
Last updated: January 8, 2014
Last verified: December 2013

September 6, 2006
January 8, 2014
October 2006
December 2008   (final data collection date for primary outcome measure)
Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With RAD001. [ Time Frame: Two cycles of treatment with RAD001 (~6 weeks) ] [ Designated as safety issue: Yes ]
Determine the proportion of previously treated small cell lung cancer (SCLC) patients whose disease has not progressed following 6-weeks (2 cycles) of treatment with RAD001.
Complete list of historical versions of study NCT00374140 on ClinicalTrials.gov Archive Site
To Determine Overall Survival, Progression-free Survival, Objective Response Rate, and Toxicities. [ Time Frame: Followed until progression and death ] [ Designated as safety issue: Yes ]
To determine overall survival, progression-free survival, objective response rate, and toxicities.
Not Provided
Not Provided
 
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.

This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. Patients may have received up to 2 prior chemotherapy regimens for small cell lung carcinoma, but no prior therapy with an m-TOR inhibitor. RAD001 will be administered orally at a dose of 10 mg daily. A cycle will be defined as 3 weeks of study drug administration, and patients will have tumor measurements every 2 cycles. Study participation will continue until disease progression or intolerable toxicities. In addition, in patients who consent, archival tumor tissue (paraffin block from original biopsy) will be collected for research purposes.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Small Cell Lung Cancer
Drug: RAD001 (everolimus)
10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
Other Name: Certican®
Active Comparator: RAD001 (Everolimus)
RAD001 (Everolimus)10 mg by mouth daily without interruption
Intervention: Drug: RAD001 (everolimus)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
July 2012
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Cytologically or histologically confirmed small cell carcinoma of the lung that has progressed post first-line therapy. Mixed small and non-small cell tumors are excluded.
  2. Prior chemotherapy for small cell carcinoma. Up to 2 prior chemotherapy regimens for small cell lung carcinoma are allowed. No prior therapy with an m-TOR inhibitor (e.g. CCI-779).
  3. Unidimensionally measurable disease (RECIST criteria). If the only site of measurable disease is in a previously irradiated area, the patient must have documented progression of disease in this area.
  4. ECOG performance status 0-2.
  5. A minimum of 4 weeks should elapse from prior chemotherapy. Patients must have fully recovered from the effects of any prior surgery or radiation therapy or other anticancer therapies, including immunotherapy and investigational agents.
  6. No progressive brain metastases. Brain metastases should have been previously treated with surgery and/or radiation.
  7. Patients with a prior malignancy should have at least 3 years of disease-free survival. Prior curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer or other in situ malignancies are allowed.
  8. No other coexisting medical condition that would preclude full compliance with the study.
  9. Required laboratory values (obtained < 1 week prior to enrollment):

    • ANC >/= 1500/mm³
    • Platelets >/= 100,000/mm³
    • AST and ALT ≤ 3 x ULN (upper limits of normal). In patients with liver metastases AST and ALT should be < 5 x ULN.
    • Total bilirubin up to 1.5 x ULN (upper limits of normal).
  10. Age >/= 18 years and capacity to give informed consent.
  11. Patients should be advised to discontinue drugs that interact with CYP3A4 (see list of examples in Table 3.1 of the full protocol), if medically safe.
  12. All patients must have given signed, informed consent prior to registration on study.

Exclusion Criteria:

  1. Prior treatment with any investigational agent within the preceding 4 weeks.
  2. Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias active ischemic heart disease, myocardial infarction within six months, chronic liver or renal disease, active upper GI tract ulceration).
  3. A known history of HIV seropositivity.
  4. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
  5. Patients with an active, bleeding diathesis or on anticoagulation (except low dose warfarin).
  6. Pregnant and lactating women are excluded from the study because the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk.
  7. Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study.
  8. Patients should not be on chronic systemic glucocorticoids or other immunosuppressant.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00374140
06-049
Yes
Ahmad Tarhini, University of Pittsburgh
Ahmad Tarhini
Novartis Pharmaceuticals
Principal Investigator: Ahmad Tarhini, MD, PhD University of Pittsburgh
University of Pittsburgh
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP